Global R&D Pipeline
My Favorite
Hot Targets:
B7H3
Back
Total number of drugs
220
Phase II and later clinical stages
4.1%
Involving companies
268
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DB-1419 | DB-1419 | Antibody drug conjugate (ADC) | Neoplasms Urogenital Diseases | CD276 inhibitors PDL1 inhibitors TOP1 inhibitors | Duality Biologics (Suzhou) Co., Ltd. | DualityBio Inc. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | Cleavable linker | P1003 | 4 - 8 | DB-1419 | - | - | detail > | |
| ILB-3101 | ILB-3101 | Antibody drug conjugate (ADC) | Neoplasms Hemic and Lymphatic Diseases | CD276 inhibitors Tubulin inhibitors | InnoLake Pharmaceuticals (Hangzhou) Co., Ltd. | InnoLake Pharmaceuticals (Hangzhou) Co., Ltd. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | Val-Cit | Eribulin | - | ILB-3101 | - | - | detail > | |
| Betabart | Betabart | Radiolabeled antibody Therapeutic radiopharmaceuticals | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | CD276 inhibitors | The University of Texas MD Anderson Cancer Center Radiopharm Theranostics Ltd. | Radiopharm Theranostics Ltd. The University of Texas MD Anderson Cancer Center | Phase 1/2 | - | - | - | - | - | - | - | 177 Lu | - | Betabart | - | - | detail > | |
| IBI-334 | IBI-334 | Bispecific antibody | Neoplasms | CD276 inhibitors EGFR antagonists | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Biologics (Suzhou) Co. Ltd. Innovent Biologics, Inc. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | IBI-334 | - | - | detail > | |
| GD2/B7H3 CAR T-cell therapy(Yake Biotechnology) | GD2/B7H3 CAR T-cell therapy(Yake Biotechnology) | CAR-T | Neoplasms Other Diseases | CD276 modulators GD2 modulators | Shanghai Yake Biotechnology Co., Ltd | Shanghai Yake Biotechnology Co., Ltd | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | GD2/B7H3 CAR T-cell therapy(Yake Biotechnology) | - | - | detail > | |
| Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University) | Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University) | Autologous CAR-T | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases | CD276 inhibitors | 徐州医科大学附属医院 | 徐州医科大学附属医院 | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | Anti-B7-H3 CAR-T (Affiliated Hospital of Xuzhou Medical University) | - | - | detail > | |
| 131I-Omburtamab | 131I-Omburtamab | Radiolabeled antibody Diagnostic radiopharmaceuticals | Neoplasms Other Diseases Nervous System Diseases Digestive System Disorders | CD276 inhibitors | Y-mAbs Therapeutics, Inc. | Y-mAbs Therapeutics, Inc. SciClone Pharmaceuticals LLC | NDA/BLA | - | - | - | - | Breakthrough Therapy（United States） Orphan Drug（European Union） Orphan Drug（United States） Priority Review（United States） Rare Pediatric Disease（United States） | - | - | 131 I | - | 131I-Omburtamab | IgG1 - kappa | - | detail > | |
| 7MW-3711 | 7MW-3711 | Antibody drug conjugate (ADC) | Neoplasms | CD276 inhibitors TOP1 inhibitors | Mabwell (Shanghai) Bioscience Co., Ltd. | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Phase 1/2 | - | - | - | Orphan Drug（United States） | - | - | - | - | 7MW-3711 | - | - | detail > | |
| MHB088C | MHB088C | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases Urogenital Diseases | CD276 inhibitors | Minghui Pharmaceutical Pty Ltd | Minghui Pharmaceutical (Hangzhou) Co., Ltd. Qilu Pharmaceutical Co., Ltd. Minghui Pharmaceutical Pty Ltd | Phase 3 | Phase 3 | - | - | - | - | - | Cleavable linker | - | - | MHB088C | - | - | detail > | |
| B7H3-IRDye800CW | B7H3-IRDye800CW | Other diagnostic agent | Neoplasms Skin and Musculoskeletal Diseases Other Diseases | CD276 modulators | Simcere Pharmaceutical Group Ltd. | Simcere Pharmaceutical Group Ltd. Peking University People's Hospital | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | B7H3-IRDye800CW | - | - | detail > |
Total 220 data
1
2
3
4
5
6
...
21
22
